142 related articles for article (PubMed ID: 20706845)
1. Intracranial hypertension following intrathecal administration of liposomal cytarabine.
Lunskens S; Lammertijn L; Deeren D; Bergmans B; Maertens J; Vandenberghe R
J Neurol; 2011 Jan; 258(1):162-3. PubMed ID: 20706845
[No Abstract] [Full Text] [Related]
2. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
Stacchini A; Demurtas A; Aliberti S
Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
[TBL] [Abstract][Full Text] [Related]
3. Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings.
Counsel P; Khangure M
Clin Radiol; 2007 Feb; 62(2):172-6. PubMed ID: 17207701
[No Abstract] [Full Text] [Related]
4. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
8. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
Hartz B; Löbel U; Hagel C; Escherich G
Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
[No Abstract] [Full Text] [Related]
9. Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration.
Butto A; Al-Holou WN; Junck L; Sagher O; Fletcher JJ
J Clin Neurosci; 2011 Oct; 18(10):1417-8. PubMed ID: 21764318
[TBL] [Abstract][Full Text] [Related]
10. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of liposomal cytarabine in neoplastic meningitis].
Rudà R; Leoncini B; Laguzzi E; Trevisan E; Guarneri D; Bertetto O; Soffietti R
Tumori; 2007; 93(3):suppl 4-5. PubMed ID: 17679479
[No Abstract] [Full Text] [Related]
13. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
15. Accidental overdose of intrathecal cytarabine in children.
Thienprayoon R; Heym KM; Pelfrey L; Bowers DC
Ann Pharmacother; 2013 May; 47(5):e24. PubMed ID: 23606548
[TBL] [Abstract][Full Text] [Related]
16. [Spinal subacute combined degeneration after intrathecal chemotherapy. Report of two cases].
Cartier R L; Parra V J; Puga B; Cardemil D
Rev Med Chil; 2018 Jun; 146(6):802-807. PubMed ID: 30148913
[TBL] [Abstract][Full Text] [Related]
17. [Cerebrospinal fluid examination after liposomal cytarabine intrathecal injection].
Guillaume C; Vegas H; Pastuszka A; Le Brun C; Lanotte P
Ann Biol Clin (Paris); 2018 Oct; 76(5):568-570. PubMed ID: 30154068
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.
Peyrl A; Sauermann R; Chocholous M; Azizi AA; Jäger W; Höferl M; Slavc I
Clin Pharmacokinet; 2014 Feb; 53(2):165-73. PubMed ID: 24129691
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis.
Jahn F; Jordan K; Behlendorf T; Globig C; Schmoll HJ; Müller-Tidow C; Jordan B
Oncology; 2015; 89(3):137-42. PubMed ID: 25791073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
